Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.47 per share when it actually produced a loss of $0.43, delivering a surprise of 8.51%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Allogene Therapeuti ...